Hostile bid prompts Commerce.com (NASDAQ: CMRC) rights plan after 47% bid
Rhea-AI Filing Summary
Commerce.com, Inc. adopted a limited-duration stockholder rights plan in response to an unsolicited acquisition proposal from Rezolve Ai PLC that the Board concluded significantly undervalues the company. The Rezolve Ai offer proposed one Rezolve Ai share for every two Commerce.com shares, implying a 47% discount to Commerce.com’s share price based on Rezolve Ai’s $2.88 closing price on April 7, 2026.
Under the Rights Agreement, stockholders of record on April 27, 2026 receive one right for each common share. If any holder reaches 10% ownership, or 20% for a Passive Institutional Investor, without Board approval, each right (other than those of the acquirer) lets holders buy shares valued at twice the $13.00 exercise price, causing heavy dilution to an unapproved acquirer. The plan expires on April 12, 2027 unless earlier redeemed or exchanged.
Positive
- None.
Negative
- None.
Insights
Commerce.com adopts a one-year poison pill to counter a steeply discounted takeover bid.
Commerce.com has implemented a stockholder rights plan after receiving an unsolicited offer from Rezolve Ai that implied a 47% discount to Commerce.com’s share price, based on Rezolve Ai’s $2.88 closing price on April 7, 2026. The Board determined the proposal significantly undervalues the business and declined further engagement.
The plan issues one right per common share as of April 27, 2026, with each right exercisable at $13.00 per one‑thousandth share of Series A Junior Participating Preferred Stock if any shareholder reaches 10% ownership, or 20% for a Passive Institutional Investor, without Board approval. This would let other holders buy stock at terms designed to deliver shares worth twice the exercise price, substantially diluting an unapproved acquirer.
The rights plan is scheduled to expire on April 12, 2027, and the Board can redeem the rights for $0.01 each before anyone becomes an acquiring person. This structure provides negotiating leverage and time around potential transactions while preserving the Board’s ability to redeem the pill if it later supports a deal.